No Carolina / NY / Florida
Ph: 561.316.3330

Neogap Secures EU Patent for Innovative Personalized Immunotherapy Technology

The Swedish biotechnology company has secured a patent in the EU for their distinctive technology used in cancer treatment. The patent covers the company's technology for multiplying T-cells, known as EpiTCer®, used in personalized immunotherapy.

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • In December of last year, Neogap announced that the company’s patent application for the European market was being prepared for approval through a “Notice of Allowance”.
  • Neogap has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumor-specific T-cells.
  • Our focus is to develop our treatments for personalized immunotherapy, to increase survival rates, and improve the quality of life for cancer patients,”.

In December of last year, Neogap announced that the company’s patent application for the European market was being prepared for approval through a “Notice of Allowance”. Neogap has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumor-specific T-cells. The patent, valid until 2038, ensures that Neogap’s EpiTCer® technology is patent protected across various markets.

“We are pleased that Neogap has been granted this patent in Europe. Our continuous evaluation of intellectual property rights ensures the protection of our unique cancer therapies. Our focus is to develop our treatments for personalized immunotherapy, to increase survival rates, and improve the quality of life for cancer patients,” says Samuel Svensson, CEO of Neogap.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

By using this website you agree to accept Medical Device News Magazine Privacy Policy